myelodysplastic syndrome
Conditions
Interventions
experimental group:Recombinant human thrombopoietin promotes platelet
control group:Do not use Recombinant human thrombopoietin promotes platelet and other platelet drugs
Sponsors
People's Hospital of Henan Provincial
Eligibility
Sex/Gender
All
Age
15 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients between 14 and 70 years old, male or female; According to who-mdra2, the diagnosis of mdra2 was confirmed. 3. Patients with ECoG behavioral status score of 0-3; 4. Patients with expected survival time >= 3 months; 5. Patients without severe heart, lung, liver and kidney diseases; 6. Patients who have the ability to understand and are willing to sign the informed consent of this trial.
Exclusion criteria
Exclusion criteria: 1. Patients who were allergic to the drugs included in the trial protocol or drugs with similar chemical structure to the tested drugs in the past; 2. Pregnant and lactating women and patients of childbearing age who are unwilling to take contraceptive measures; 3. Patients with active infection; 4. Patients with extramedullary lesions; 5. Patients who take drugs or drink too much for a long time to affect the evaluation of the test results; 6. Patients with mental disorders or other conditions who can not obtain informed consent can not cooperate with the requirements of completing the trial treatment and examination steps; 7. Patients with prolonged QTc interval of clinical significance (male > 450 ms, female > 470 MS), ventricular tachycardia (VT), atrial fibrillation (AF), degree II or above heart block, myocardial infarction (MI) within 1 year, congestive heart failure (CHF), symptomatic coronary heart disease requiring drug treatment; 8. Patients with abnormal liver function (total bilirubin > 1.5 times of the upper limit of normal value, ALT / AST > 2.5 times of the upper limit of normal value, or ALT / AST > 5 times of the upper limit of normal value in patients with liver invasion), and abnormal renal function (serum creatinine > 1.5 times of the upper limit of normal value); 9. Patients not suitable for this trial according to the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| recovery time of platelets; | — |
Secondary
| Measure | Time frame |
|---|---|
| The amount of platelet transfusion;hospital stays;Bleeding score;treatment respond;adverse reaction;survival time; | — |
Countries
China
Contacts
Public ContactChen Xiangli
People's Hospital of He'nan Province
Outcome results
None listed